SG11201803958WA - Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences - Google Patents
Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequencesInfo
- Publication number
- SG11201803958WA SG11201803958WA SG11201803958WA SG11201803958WA SG11201803958WA SG 11201803958W A SG11201803958W A SG 11201803958WA SG 11201803958W A SG11201803958W A SG 11201803958WA SG 11201803958W A SG11201803958W A SG 11201803958WA SG 11201803958W A SG11201803958W A SG 11201803958WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- nucleic acid
- amino acid
- repetitive
- rich
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C12N15/68—Stabilisation of the vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
- C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
- C12Q2537/165—Mathematical modelling, e.g. logarithm, ratio
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau (43) International Publication Date .... ....7:01 29 June 2017(29.06.2017) WIPO I PCT (10) WO International 111111111111311111111111111111111111111111111111111111111111111111111111111111111111111111 2017/109087 Publication Al Number (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12N 15/62 (2006.01) C12N 15/11 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 38/00 (2006.01) C12N 15/64 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, C07K 14/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, ICH, KN, PCT/EP2016/082407 KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (22) International Filing Date: MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, 22 December 2016 (22.12.2016) NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (25) Filing Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (26) Publication Language: English ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 15202093.9 22 December 2015 (22.12.2015) EP kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicants: XL-PROTEIN GMBH [DE/DE]; Lise-Meit- TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, ner-Str. 30, 85354 Freising (DE). TECHNISCHE UNI- TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, VERSITAT MUNCHEN [DE/DE]; Arcisstras se 21, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, 80333 Miinchen (DE). LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (72) Inventors: BINDER, Ulrich; Angerstr. 7, 85354 Freising SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (DE). ACHATZ, Stefan; Max-Lehner-Str. 24, 85354 Fre- ising (DE). SKERRA, Arne; Max-Lehner-Str. 19, 85354 Published: Freising (DE). 21(3)) — with international search report (Art (74) Agent: MEIER, Jurgen; Vossius & Partner, SiebertstraBe _ with sequence listing part of description (Rule 5.2(a)) 3, 81675 Miinchen (DE). 1-1 .4t N (54) Title: NUCLEIC ACIDS ENCODING REPETITIVE AMINO ACID SEQUENCES RICH IN PROLINE AND ALANINE GC RESIDUES THAT HAVE LOW REPETITIVE NUCLEOTIDE SEQUENCES 0 C(57) : The present invention relates to a nucleic acid molecule comprising a low repetitive nucleotide sequence encoding a • Il prolme/alanine-rich amino acid repeat sequence. The encoded polypeptide comprises a repetitive amino acid sequence that forms a *----- random coil. The nucleic acid molecule comprising said low repetitive nucleotide sequences can further comprise a nucleotide se - L -- quence encoding a biologically or pharmacologically active protein. Further, the present invention provides for selection means and ::::) methods to identify said nucleic acid molecule comprising said low repetitive nucleotide sequence. The present invention also relates ei to a method for preparing said nucleic acid molecules. Also provided herein are methods for preparing the encoded polypeptide or 0 drug conjugates with the encoded polypeptide using the herein provided nucleic acid molecules. The drug conjugate may comprise a biologically or pharmacologically active protein or a small molecule drug. Also provided herein are vectors and hosts comprising 5 such nucleic acid molecules.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15202093 | 2015-12-22 | ||
PCT/EP2016/082407 WO2017109087A1 (en) | 2015-12-22 | 2016-12-22 | Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201803958WA true SG11201803958WA (en) | 2018-07-30 |
Family
ID=55129435
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201803958WA SG11201803958WA (en) | 2015-12-22 | 2016-12-22 | Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences |
Country Status (19)
Country | Link |
---|---|
US (1) | US11401305B2 (en) |
EP (2) | EP3919623A1 (en) |
JP (1) | JP7065772B2 (en) |
KR (1) | KR102654180B1 (en) |
CN (1) | CN109153996B (en) |
AU (1) | AU2016378646B2 (en) |
BR (1) | BR112018012784A2 (en) |
CA (1) | CA3005115A1 (en) |
DK (1) | DK3394266T3 (en) |
EA (1) | EA201891127A1 (en) |
ES (1) | ES2877539T3 (en) |
HU (1) | HUE055267T2 (en) |
IL (1) | IL259352B (en) |
LT (1) | LT3394266T (en) |
MX (1) | MX2018007680A (en) |
PL (1) | PL3394266T3 (en) |
SG (1) | SG11201803958WA (en) |
SI (1) | SI3394266T1 (en) |
WO (1) | WO2017109087A1 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
EP3092049A1 (en) | 2014-01-08 | 2016-11-16 | Flodesign Sonics Inc. | Acoustophoresis device with dual acoustophoretic chamber |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
US10174302B1 (en) | 2017-06-21 | 2019-01-08 | Xl-Protein Gmbh | Modified L-asparaginase |
EP3710483A4 (en) * | 2017-11-16 | 2021-10-20 | XL-protein GmbH | Pasylated vegfr/pdgfr fusion proteins and their use in therapy |
CN111406071B (en) * | 2017-11-16 | 2024-01-16 | 成都硕德药业有限公司 | PAS-like VEGFR/PDGFR fusion proteins and their use in therapy |
KR20220066413A (en) | 2017-12-14 | 2022-05-24 | 프로디자인 소닉스, 인크. | Acoustic transducer drive and controller |
US12016889B2 (en) | 2018-02-23 | 2024-06-25 | 9 Meters Biopharma, Inc. | Compositions and methods for treating or preventing intestinal paracellular permeability |
KR102209198B1 (en) * | 2019-04-02 | 2021-02-02 | 주식회사 바이오앱 | Recombinant Irisin gene optimized for plant expression and method for producing recombinant Irisin protein therefrom |
CN110038120B (en) * | 2019-04-02 | 2022-12-23 | 河南师范大学 | Application of rana pipiens anti-tumor enzyme fusion protein as tumor treatment drug |
US20200327961A1 (en) * | 2019-04-15 | 2020-10-15 | Bruker Daltonik Gmbh | Methods for determining isomeric amino acid residues of proteins and peptides |
WO2020227341A1 (en) * | 2019-05-06 | 2020-11-12 | 9 Meters Biopharma, Inc. | Compositions and methods for treating sjogren's syndrome |
AU2021405029A1 (en) | 2020-12-22 | 2023-07-20 | Technische Universität München | Antibodies specific for structurally disordered sequences |
CN113340864B (en) * | 2021-06-07 | 2023-04-07 | 郑州轻工业大学 | Aptamer sensor for secondary amplification of INS signal based on MEF effect and preparation method and application thereof |
CN114470170B (en) * | 2022-02-22 | 2023-09-19 | 广州新济药业科技有限公司 | Semiglutide soluble microneedle composition and preparation method thereof |
WO2024042236A1 (en) | 2022-08-26 | 2024-02-29 | Ethris Gmbh | Stable lipid or lipidoid nanoparticle suspensions |
GB202218084D0 (en) | 2022-12-01 | 2023-01-18 | Volution Immuno Pharmaceuticals Sa | Fusion proteins |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
CA2164088C (en) | 1993-06-07 | 2005-06-14 | Gary J. Nabel | Plasmids suitable for gene therapy |
AU723325B2 (en) | 1995-06-23 | 2000-08-24 | President And Fellows Of Harvard College | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
US7378506B2 (en) | 1997-07-21 | 2008-05-27 | Ohio University | Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins |
US20060252120A1 (en) | 2003-05-09 | 2006-11-09 | Kieliszewski Marcia J | Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins |
JP2009538622A (en) | 2006-05-30 | 2009-11-12 | ダウ グローバル テクノロジーズ インコーポレイティド | Codon optimization method |
DK2173890T3 (en) | 2007-06-21 | 2011-06-27 | Univ Muenchen Tech | Biologically active proteins with increased stability in vivo and / or in vitro |
WO2011144756A1 (en) | 2010-05-21 | 2011-11-24 | Xl-Protein Gmbh | Biosynthetic proline/alanine random coil polypeptides and their uses |
US9975929B2 (en) | 2014-03-05 | 2018-05-22 | Merz Pharma Gmbh & Co. Kgaa | Recombinant clostridial neurotoxins with increased duration of effect |
CN110891612A (en) | 2017-06-21 | 2020-03-17 | Xl-蛋白有限责任公司 | Conjugates of protein drugs and P/A peptides |
US10174302B1 (en) | 2017-06-21 | 2019-01-08 | Xl-Protein Gmbh | Modified L-asparaginase |
KR20200030065A (en) | 2017-06-21 | 2020-03-19 | 재즈 파마슈티칼즈 아일랜드 리미티드 | Modified L-asparaginase |
EP3418383A1 (en) | 2017-06-21 | 2018-12-26 | XL-protein GmbH | Modified l-asparaginase |
EP3710483A4 (en) | 2017-11-16 | 2021-10-20 | XL-protein GmbH | Pasylated vegfr/pdgfr fusion proteins and their use in therapy |
-
2016
- 2016-12-22 EP EP21166789.4A patent/EP3919623A1/en not_active Withdrawn
- 2016-12-22 SI SI201631254T patent/SI3394266T1/en unknown
- 2016-12-22 PL PL16828736T patent/PL3394266T3/en unknown
- 2016-12-22 KR KR1020187020867A patent/KR102654180B1/en active IP Right Grant
- 2016-12-22 AU AU2016378646A patent/AU2016378646B2/en active Active
- 2016-12-22 WO PCT/EP2016/082407 patent/WO2017109087A1/en active Application Filing
- 2016-12-22 US US16/064,951 patent/US11401305B2/en active Active
- 2016-12-22 EP EP16828736.5A patent/EP3394266B1/en active Active
- 2016-12-22 BR BR112018012784A patent/BR112018012784A2/en active Search and Examination
- 2016-12-22 MX MX2018007680A patent/MX2018007680A/en unknown
- 2016-12-22 CN CN201680072372.2A patent/CN109153996B/en active Active
- 2016-12-22 LT LTEP16828736.5T patent/LT3394266T/en unknown
- 2016-12-22 JP JP2018532638A patent/JP7065772B2/en active Active
- 2016-12-22 SG SG11201803958WA patent/SG11201803958WA/en unknown
- 2016-12-22 EA EA201891127A patent/EA201891127A1/en unknown
- 2016-12-22 DK DK16828736.5T patent/DK3394266T3/en active
- 2016-12-22 ES ES16828736T patent/ES2877539T3/en active Active
- 2016-12-22 HU HUE16828736A patent/HUE055267T2/en unknown
- 2016-12-22 CA CA3005115A patent/CA3005115A1/en active Pending
-
2018
- 2018-05-14 IL IL259352A patent/IL259352B/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP7065772B2 (en) | 2022-05-12 |
EP3919623A1 (en) | 2021-12-08 |
IL259352B (en) | 2022-02-01 |
JP2019508020A (en) | 2019-03-28 |
IL259352A (en) | 2018-07-31 |
AU2016378646A1 (en) | 2018-06-14 |
CN109153996A (en) | 2019-01-04 |
HUE055267T2 (en) | 2021-11-29 |
LT3394266T (en) | 2021-08-25 |
ES2877539T3 (en) | 2021-11-17 |
US20190010192A1 (en) | 2019-01-10 |
WO2017109087A1 (en) | 2017-06-29 |
US11401305B2 (en) | 2022-08-02 |
EP3394266A1 (en) | 2018-10-31 |
KR102654180B1 (en) | 2024-04-04 |
CA3005115A1 (en) | 2017-06-29 |
SI3394266T1 (en) | 2021-08-31 |
KR20180088484A (en) | 2018-08-03 |
PL3394266T3 (en) | 2021-12-13 |
AU2016378646B2 (en) | 2023-03-09 |
BR112018012784A2 (en) | 2019-02-05 |
CN109153996B (en) | 2022-03-25 |
EA201891127A1 (en) | 2019-01-31 |
EP3394266B1 (en) | 2021-04-14 |
MX2018007680A (en) | 2018-11-14 |
DK3394266T3 (en) | 2021-06-07 |
NZ742902A (en) | 2023-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201803958WA (en) | Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences | |
SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201803593QA (en) | Engineered nucleic-acid targeting nucleic acids | |
SG11201907298WA (en) | Methods and compositions for gene transfer across the vasculature | |
SG11201807912SA (en) | Vaccine against rsv | |
SG11201909918XA (en) | Compositions and methods for improving sample identification in indexed nucleic acid libraries | |
SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201908280SA (en) | "chimeric molecules and uses thereof" | |
SG11201901206SA (en) | Trimer stabilizing hiv envelope protein mutations | |
SG11201901066UA (en) | Novel alkaline stable immunoglobulin-binding proteins | |
SG11201804729RA (en) | Methods and compositions for treating a serpinc1-associated disorder | |
SG11201806905UA (en) | Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers | |
SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201906341XA (en) | Improved serum albumin binders | |
SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
SG11201907769XA (en) | Cd80 variant immunomodulatory proteins and uses thereof | |
SG11201408153YA (en) | Prostate-specific membrane antigen antibody drug conjugates | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
SG11201808710UA (en) | Novel immunogenic cd1d binding peptides |